Novavax employs AI-based dose selection for Covid-influenza vaccine trials

Covid-19 boosters continue to be used due to the ongoing circulation of the virus, the emergence of new variants, and decreasing neutralising antibody responses among individuals. Similarly, unmet needs remain for more effective annual seasonal influenza vaccines. In an effort to simultaneously address these two major public health concerns, Novavax is developing a Covid-Influenza Combination (CIC) vaccine, which is currently in Phase II development.